Jésus Martinez de la Fuente
Country of residence
Instituto de Nanociencia de Aragon
Dr. J.M. de la Fuente (Barakaldo, 1975) started his PhD work in 1999 working in the evaluation of carbohydrate-carbohydrate interactions using gold nanoparticles in the Institute of Chemical Research from CSIC (Spanish National Research Council). During his PhD, he prepared the first gold nanoparticles functionalized using biologically relevant oligosaccharides, providing the first thermodynamic data, adhesion forces and kinetic data of the carbohydrate-carbohydrate interactions for the antigen Lewis X and also intervened in biological processes.
Once he obtained his PhD, he was funded by the Spanish Science Ministry to work in the Centre for Cell Engineering University of Glasgow (UK) to develop a research project involving the nanoparticles development and its biological application during two years. Midatech Ltd., a British start-up company, found very interesting the biofuncionalized nanoparticles developed in Glasgow. An American patent has been licentiate to this company.
In July 2005, he went back to the Institute of Chemical Research (IIQ)-CSIC (Seville, Spain). His research was oriented to the vectorization of paramagnetic nanoparticles with biologically relevant carbohydrates to label and visualize brain tumors.
In June 2007, he got a permanent position in the Institute of Nanoscience of Aragon (INA) belonging to the University of Zaragoza (Spain) as Senior Researcher supported by ARAID. He is actually leading the research group specialized in the Biofunctionalization of Nanoparticles and Surfaces. His research interest is based on the development of general and simple strategies for the functionalization of nanoparticles and surfaces for biomedical and biotechnological applications. He has actually more than 90 published articles with more than 2500 citations and 5 international patents. He is actually coordinating an ERC-Starting Grant and an ERANET projects in the field of Nanotherapy. He obtained the award ARAGON-INVESTIGA in 2010. He is also co-founder of the spin-off NANOIMMUNOTECH S.L.